Moderna Shares Jump 13% on Hantavirus Outbreak

Moderna stock surged 13% after news of Andes‑strain Hantavirus outbreak on cruise ship MV Hondius infecting ~10 people, killing three.
Bernstein maintains Market‑Perform rating with $45 price target, implying 17% downside from May 8 close of $54.35.
Analysts say Andes strain’s human‑to‑human spread is localized, making a global pandemic unlikely despite 30‑40% HCPS mortality.
Moderna could develop mRNA Hantavirus vaccine in preclinical stage with partners Korea University and USAMRIID; costs > $500 million, likely funded by governments.